Patents Issued in June 19, 2018
-
Patent number: 10000547Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: March 28, 2016Date of Patent: June 19, 2018Assignee: IMMATICS BIOTECHNOLOGY GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
-
Patent number: 10000548Abstract: Galectin-1 polypeptide variants that include a mutation of the histidine residue corresponding to position 52 of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the mutation being a substitution of the histidine to tyrosine or asparagine, providing resistance to acidosis otherwise resulting in deactivation of the native human Gal-1. The Galectin-1 polypeptide variants may include one or more additional mutation(s) of the cysteine residue corresponding to a position selected from 2, 16, 88, or combinations thereof of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the additional mutation being a substitution of the cysteine to serine, and providing resistance to oxidation.Type: GrantFiled: April 21, 2016Date of Patent: June 19, 2018Assignees: Consejo Nacional de Investigaciones Cientificas Y Técnicas, Fundación Sales, INIS Biotech LLCInventors: Gabriel Adrián Rabinovich, Santiago Di Lella, Dario Ariel Estrin, Julio Javier Carmelo, Santiago Patricio Mendez Huergo
-
Patent number: 10000549Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.Type: GrantFiled: June 9, 2016Date of Patent: June 19, 2018Assignees: KAHR Medical Ltd., Hadasit Medical Research Services and Development Ltd.Inventor: Michal Dranitzki Elhalel
-
Patent number: 10000550Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: December 2, 2016Date of Patent: June 19, 2018Assignee: Apogenix AGInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Patent number: 10000551Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.Type: GrantFiled: September 10, 2015Date of Patent: June 19, 2018Assignee: Protalix Ltd.Inventors: Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Tami Ariel, Svetlana Gingis-Velitski, Myriam Golembo
-
Patent number: 10000552Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID NO: 2. The TRAIL CPPs-like mutant selectively transforms the amino acid coding sequence of No. 114-118 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERG to RRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence and glycine into arginine on the 118th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of five arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL CPPs-like mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.Type: GrantFiled: May 10, 2017Date of Patent: June 19, 2018Assignee: CHENGDU HUACHUANG BIOTECHNOLOGY CO., LTDInventors: Shouchun Chen, Juan Yan, Qi Xu, Xianzhou Huang, Lijia Wei, Haiyang Hu
-
Patent number: 10000553Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.Type: GrantFiled: October 10, 2012Date of Patent: June 19, 2018Assignee: Viela Bio, Inc.Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
-
Patent number: 10000554Abstract: A modified laminin characterized in that a laminin or a heterotrimeric laminin fragment has a collagen binding molecule conjugated to at least one site selected from the ? chain N-terminus, the ? chain N-terminus and the ? chain N-terminus, and an extracellular-matrix material comprising the modified laminin, and collagen and/or gelatin serve as an alternative to Matrigel and are useful as an extracellular-matrix material for the formation of a safe three-dimensional tissue structure for regenerative medicine in humans.Type: GrantFiled: November 11, 2013Date of Patent: June 19, 2018Assignee: OSAKA UNIVERSITYInventors: Kiyotoshi Sekiguchi, Shaoliang Li, Ryoko Sato
-
Patent number: 10000555Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.Type: GrantFiled: November 1, 2012Date of Patent: June 19, 2018Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Toni Beth Kline
-
Patent number: 10000556Abstract: Isolated VHH monoclonal antibodies are disclosed that specifically bind to a Norovirus polypeptide. In some embodiments, the Norovirus is a Genogroup I Norovirus or a Genogroup II Norovirus. In other embodiments, the Norovirus is Norwalk or MD2004 virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. Also disclosed are methods of treating and/or preventing a NoV infection.Type: GrantFiled: May 9, 2014Date of Patent: June 19, 2018Assignees: THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human Services, INSTITUTO NACIONAL DE TECHNOLOGIA AGROPECUARIAInventors: Karin Bok, Lorena Laura Garaicoechea, Viviana Parreno, Andrea Pamela Aguilar, Marina Bok, Lisbeth Kim Green, Stanislav Vladimirovich Sosnovtsev
-
Patent number: 10000557Abstract: The present invention generally relates to methods of generating antibodies against a species of pathogen that involve identifying the pathogen that is most genetically representative of member of pathogen species and using the identified pathogen to generate an antibody.Type: GrantFiled: December 18, 2013Date of Patent: June 19, 2018Assignee: DNAE Group Holdings LimitedInventors: Colin Dykes, Sergey A. Dryga, Lisa-Jo Ann Clarizia, Eddie W. Adams, Meghan Norvell
-
Patent number: 10000558Abstract: Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.Type: GrantFiled: August 16, 2016Date of Patent: June 19, 2018Assignee: VERSITECH LIMITEDInventors: Stephanie Kwai Yee Ma, Man Tong, Xin-Yuan Guan
-
Patent number: 10000559Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.Type: GrantFiled: July 11, 2017Date of Patent: June 19, 2018Assignee: Janssen Biotech, Inc.Inventors: Christopher Alderfer, Dariusz Janecki, Xuesong Liu, Melissa Murdock, Sheng-Jiun Wu, Marc Mercken, Marc Vandermeeren, Thomas Malia
-
Patent number: 10000560Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: GrantFiled: December 18, 2015Date of Patent: June 19, 2018Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Taichi Kuramochi, Hiroyasu Muramatsu, Atsunori Ueyama, Tomoyuki Igawa, Hitoshi Katada, Yuji Hori
-
Patent number: 10000561Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.Type: GrantFiled: September 7, 2016Date of Patent: June 19, 2018Assignee: NOVARTIS AGInventors: Matthew John Edwards, Jean-Michel Rene Rondeau, Danforth Miller, Daniel Huang, Hans-Peter Knopf, Gino Anselmus Van Heeke, Rene Hemmig, Kapil Gupta, Nicole Haubst, Barbara Andlauer
-
Patent number: 10000562Abstract: Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations.Type: GrantFiled: April 23, 2014Date of Patent: June 19, 2018Assignee: GENENTECH, INC.Inventors: Ajay Deshmukh, Joumana Zeid, Thomas M. Scherer
-
Patent number: 10000563Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: July 12, 2016Date of Patent: June 19, 2018Assignee: ZYMOGENETICS, INC.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 10000564Abstract: The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.Type: GrantFiled: August 26, 2016Date of Patent: June 19, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
-
Patent number: 10000565Abstract: The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.Type: GrantFiled: November 14, 2013Date of Patent: June 19, 2018Assignee: Novartis AGInventors: Craig Basson, Mark Fishman, Tom Thuren, Shi Yin Foo
-
Patent number: 10000566Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: May 13, 2016Date of Patent: June 19, 2018Assignee: IMMUNOGEN, INC.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Patent number: 10000567Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.Type: GrantFiled: March 12, 2013Date of Patent: June 19, 2018Assignee: Therapix Biosciences Ltd.Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
-
Patent number: 10000568Abstract: The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.Type: GrantFiled: April 10, 2009Date of Patent: June 19, 2018Assignee: Cell Signaling Technology, Inc.Inventors: Ting-Lei Gu, Jiong Wu, Susan Kane, Jian Yu, Herbert Haack, James Wieler, Jun-Ming Cai, Victoria Rimkunas
-
Patent number: 10000569Abstract: An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.Type: GrantFiled: April 22, 2015Date of Patent: June 19, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kwang Ho Cheong, Jae Woong Hwang, Seung Hyun Lee, Powei Lin, Mi Young Cho
-
Patent number: 10000570Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.Type: GrantFiled: June 15, 2015Date of Patent: June 19, 2018Assignee: Genmab A/SInventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
-
Patent number: 10000571Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: September 15, 2016Date of Patent: June 19, 2018Assignee: Genentech, Inc.Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
-
Patent number: 10000572Abstract: The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-? and uses thereof.Type: GrantFiled: August 1, 2014Date of Patent: June 19, 2018Assignees: UNIVERSITÉ CATHOLIQUE DE LOUVAIN, LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld
-
Patent number: 10000573Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: May 31, 2017Date of Patent: June 19, 2018Assignees: CENTRO DE IMMUNOLOGIA MOLECULAR, BIOCON LIMITEDInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 10000574Abstract: The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding sites specifically binds the human CD3 antigen. The polypeptide may exist in both monomeric form and multimeric form. The multimeric form of the polypeptide constitutes no more than 5% of the total weight of the combined monomeric and multimeric forms of said polypeptide.Type: GrantFiled: November 26, 2004Date of Patent: June 19, 2018Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Robert Hofmeister, Nadja Prang, Andreas Wolf, Frank Hanakam, Thomas Urbig, Christian Itin, Patrick Baeuerle
-
Patent number: 10000575Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.Type: GrantFiled: April 29, 2014Date of Patent: June 19, 2018Assignees: OGD2 PHARMA, UNIVERSITE DE NANTESInventors: Stephane Birkle, Denis Cochonneau, Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
-
Patent number: 10000576Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.Type: GrantFiled: January 5, 2018Date of Patent: June 19, 2018Assignee: Zymeworks Inc.Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
-
Patent number: 10000577Abstract: A method of treating otitis media in a subject is described that includes administering to the subject a therapeutically effective amount of an Actin-Related Protein 2/3 Complex (Arp2/3) inhibitor. The role of Arp2/3 in otitis media was identified using comprehensive proteomic and metabolomic studies of otitis media using the chinchilla model.Type: GrantFiled: September 11, 2015Date of Patent: June 19, 2018Assignee: Research Institute At Nationwide Children's HospitalInventors: Sheryl S. Justice, Kevin M. Mason, Alistair Harrison
-
Patent number: 10000578Abstract: Methods for isolating cellulose nanocrystals (CNCs) from the plant Miscanthus Giganteus (MxG). Impressive yields are obtained through a combination of processing steps including base hydrolysis, bleaching and acid hydrolysis. MxG-CNCs are produced having high aspect ratios, are biorenewable and can be used for a wide range of applications such as nanofillers in composites. MxG-CNC-containing composites are also disclosed.Type: GrantFiled: December 19, 2014Date of Patent: June 19, 2018Assignee: Case Western Reserve UniversityInventors: Stuart Rowan, Mo Hunsen, Amanda Way
-
Patent number: 10000579Abstract: An integrated process for the recovery of a spectrum of commercially valuable products such as agar, cellulose, lipids, pigments and a liquid rich in minerals of agricultural importance directly from fresh seaweed without employing any catalyst driven in situ chemical conversions. Also solvents used during lipid extraction were shown to be used for three cycles without affecting the yield and quality of successive products. Furthermore, this new process is highly efficient and utilizes total seaweed raw material without any leftover biomass as solid waste.Type: GrantFiled: December 30, 2014Date of Patent: June 19, 2018Assignee: Council of Scientific & Industrial ResearchInventors: Chennur Radhakrishna Reddy, Ravi Singh Baghel, Nitin Trivedi, Puja Kumari, Vishal Gupta, Kamlesh Prasad, Ramavatar Meena
-
Patent number: 10000580Abstract: Poly alpha-1,3-glucan ester compounds are disclosed herein with a degree of substitution of about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ester compounds and films made therefrom.Type: GrantFiled: March 2, 2016Date of Patent: June 19, 2018Assignee: E I DU PONT DE NEMOURS AND COMPANYInventors: Rahul B Kasat, Jayme L Paullin
-
Patent number: 10000581Abstract: Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes various embodiments of the present invention.Type: GrantFiled: May 7, 2014Date of Patent: June 19, 2018Assignee: Purdue Research FoundationInventors: David H. Thompson, Aditya Kulkarni, Christopher Collins, Yawo Mondjinou
-
Patent number: 10000582Abstract: The present disclosure provides methods for sulfonation of hyaluronic acid. The present disclosure provides sulfonated hyaluronic acid, and compositions, including pharmaceutical compositions, comprising the sulfonated hyaluronic acid. The present disclosure provides implantable materials and drug delivery compositions comprising a subject sulfonated hyaluronic acid.Type: GrantFiled: April 1, 2014Date of Patent: June 19, 2018Assignee: The Regents of the University of CaliforniaInventors: Amit K. Jha, Eda Isil Altiok, Wesley M. Jackson, Kevin E. Healy
-
Patent number: 10000583Abstract: The present invention relates to diene-based hydrogenated polymer latex particles having a particle size measured as d90 value of less than 60 nm and a method for their production and their use. The nanosized hydrogenated diene-based polymers obtained show improved properties, especially with respect to resistance to degradation by heat, oxygen and ozone.Type: GrantFiled: August 26, 2010Date of Patent: June 19, 2018Assignee: UNIVERSITY OF WATERLOOInventors: Qinmin Pan, Garry L. Rempel
-
Patent number: 10000584Abstract: This invention relates to a novel process for selectively hydrogenating nitrile rubbers in the presence of specific Ruthenium based complex catalysts without simultaneous molecular weight degradation by a metathetic reaction.Type: GrantFiled: April 26, 2013Date of Patent: June 19, 2018Assignee: ARLANXEO DEUTSCHLAND GMBHInventors: Qingchun Liu, Zhenli Wei, Martin Hoch
-
Process for producing aromatic vinyl/conjugated diene copolymer and product of hydrogenation thereof
Patent number: 10000585Abstract: As a method for producing a copolymer with a high oil absorption rate by separating a solvent from a copolymer solution containing a copolymer in a simple manner with a less energy consumption, the present invention relates to a production method for obtaining a copolymer by separating a solvent from a copolymer solution, the method including the following Steps A to C. Step A: a step of regulating a solid component concentration (Ts) of the copolymer solution to a range of (5?Ts?60) in terms of a mass %, Step B: a step of heating the copolymer (P) solution obtained in the Step A such that a temperature T (° C.) is in a specified range, and Step C: a step of discharging the copolymer solution heated in the Step B from a specified nozzle at a linear velocity of 1 to 100 m/sec to separate the solvent in an inert gas stream at 0 to 200° C.Type: GrantFiled: December 25, 2015Date of Patent: June 19, 2018Assignee: KURARAY CO., LTD.Inventors: Tomoaki Tsuji, Masataka Shintani, Yasuhiro Hatanaka -
Patent number: 10000586Abstract: A method for producing polyvinyl alcohols by means of catalytic reactions of alcoholic polyvinyl ester solutions in extruders, wherein the polyvinyl esters are based exclusively on ethylenically unsaturated monomers and wherein one or more neutralizing agents are added to the product of the catalytic reaction.Type: GrantFiled: December 4, 2014Date of Patent: June 19, 2018Assignee: Wacker Chemie AGInventors: Thomas Köhler, Martina Belitzer, Oliver Windt
-
Patent number: 10000587Abstract: The present invention relates to a polymer fiber, in particular a polyethylene polymer fiber obtainable by melt-spinning of a polyethylene polymer, the use of the fiber and a process for the manufacture of the fiber. Further, the present invention relates to a heat sealable filter paper comprising said polymer fiber.Type: GrantFiled: July 29, 2013Date of Patent: June 19, 2018Assignee: Baumhueter Extrusion GmbhInventor: Ingo Knack
-
Patent number: 10000588Abstract: The present invention relates to coatings for a polymer, the coating comprising a diacrylate of an aliphatic diol, a polyacrylate of an aliphatic polyol, a photoinitiator, wherein the average molecular weight between cross-links in the coating is less than 190 g/mol. The invention further relates to articles comprising the coating and a polymer.Type: GrantFiled: July 13, 2012Date of Patent: June 19, 2018Assignee: Eastman Chemical CompanyInventors: Martin Frederick Schick, Amy Lee Bolton, Jayme Leita, Alisa Annette Williams, Gary Michael Stack, Scott Ellery George
-
Patent number: 10000589Abstract: A method for making a solid catalyst component for use in a Ziegler-Natta catalyst includes combining in a hydrocarbon solvent a porous particulate support with a hydrocarbon soluble organomagnesium compound to form a suspension. The organomagnesium compound is halogenated followed by addition of an alcohol and the mixture is then reacted with a titanium compound followed by a reaction with at least one diether compound to form the solid catalyst component. Afterwards the reaction product is extracted with a mixture of a titanium compound and a hydrocarbon solvent. The solid catalyst component recovered is combined with an aluminum cocatalyst to form a Ziegler-Natta catalyst system for the polymerization of olefins. In particular, the catalyst system including a diether internal electron donor may have an activity and hydrogen response suitable for the production of propylene polymers having a molecular weight distribution (PI(GPC)) in the range from about 5.75 to about 9.Type: GrantFiled: October 6, 2016Date of Patent: June 19, 2018Assignee: Lummus Novolen Technology GmbHInventors: Yvonne Denkwitz, Oliver Schuster, Andreas Winter
-
Patent number: 10000590Abstract: A chain transfer agent composition comprises at least one branched C10 mercaptan selected from 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, or combinations thereof. The chain transfer agent composition can be a component of an emulsion polymerization mixture and can be used in a process for emulsion polymerization for the production of polymers, for example, via free-radical polymerization.Type: GrantFiled: December 14, 2017Date of Patent: June 19, 2018Assignee: Chevron Phillips Chemical Company LPInventors: Jason L. Kreider, Michael S. Matson
-
Patent number: 10000591Abstract: A process for the preparation of a catalyst system for olefin polymerization, including: A) providing said procatalyst obtainable via a process comprising: i) contacting a compound R4zMgX42-z with an alkoxy- or aryloxy-containing silane compound to give a first intermediate reaction product, ii) optionally contacting the solid product obtained in step i) with at least one activating compound selected from an activating electron donor or metal alkoxide compound; iii) contacting the first or second intermediate reaction product, with a halogen-containing Ti-compound and optionally an internal electron donor to obtain the procatalyst; and B) contacting the procatalyst with a co-catalyst and at least diethylaminotriethoxysilane as the external donor.Type: GrantFiled: December 19, 2014Date of Patent: June 19, 2018Assignees: SAUDI BASIC INDUSTRIES CORPORATION, SABIC GLOBAL TECHNOLOGIES B.V.Inventors: Aurora Alexandra Batinas-Geurts, Martin Alexander Zuideveld, Raymond Gerlofsma, Henrica Norberta Alberta Maria Steenbakkers-Menting, Peter Degenhart
-
Patent number: 10000592Abstract: The present invention is a process for producing copolymers of ethylene and alpha-olefins having from 4 to 10 carbon atoms in three polymerization stages where a low molecular weight copolymer of ethylene is produced in two of the stages and a high molecular weight copolymer in one of the stages. The resulting copolymers have a low content of extractable material and can be extruded to films which can be used in food contact applications.Type: GrantFiled: December 12, 2014Date of Patent: June 19, 2018Assignee: BOREALIS AGInventors: Yi Liu, John Jamieson, Ravindra Tupe, Jarmo Kela
-
Patent number: 10000593Abstract: A catalyst system including the reaction product of a fluorided support, an activator, and at least a first transition metal catalyst compound; methods of making such catalyst systems, polymerization processes using such catalyst systems, and polymers made therefrom.Type: GrantFiled: August 19, 2016Date of Patent: June 19, 2018Assignee: ExxonMobil Chemical Patents Inc.Inventors: Xuan Ye, Crisita Carmen H. Atienza, Matthew W. Holtcamp, David F. Sanders, Gregory S. Day, Michelle E. Titone, David A. Cano, Matthew S. Bedoya
-
Patent number: 10000594Abstract: Disclosed herein are ethylene-based polymers generally characterized by a Mw ranging from 70,000 to 200,000 g/mol, a ratio of Mz/Mw ranging from 1.8 to 20, an IB parameter ranging from 0.92 to 1.05, and an ATREF profile characterized by one large peak. These polymers have the dart impact, tear strength, and optical properties of a metallocene-catalyzed LLDPE, but with improved processability, melt strength, and bubble stability, and can be used in blown film and other end-use applications.Type: GrantFiled: November 8, 2016Date of Patent: June 19, 2018Assignee: Chevron Phillips Chemical Company LPInventors: Mark L. Hlavinka, Chung Ching Tso, Yongwoo Inn, Deloris R. Gagan, Randy S. Muninger
-
Patent number: 10000595Abstract: Disclosed herein are methods for synthesizing low valence, bimetallic titanium compounds from half-metallocene titanium compounds and alkylaluminum compounds. The bimetallic titanium compounds can be used as components in catalyst systems for the polymerization of olefins.Type: GrantFiled: April 7, 2017Date of Patent: June 19, 2018Assignee: Chevron Phillips Chemical Company LPInventors: Carlos A. Cruz, Jared L. Barr
-
Patent number: 10000596Abstract: Hydrolyzed divinylbenzene/maleic anhydride polymeric materials and methods of making these polymeric materials are provided. These polymers have a high BET specific surface area that results from the presence of micropores and/or mesopores. The polymers are useful for the adsorption of low molecular weight (e.g., no greater than 150 gram/mole), basic nitrogen-containing compounds.Type: GrantFiled: December 16, 2014Date of Patent: June 19, 2018Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Michael S. Wendland, Michael W. Kobe